Form 4: TYRA COO Sells Shares Under 10b5-1 Plan

Tyra Biosciences' Chief Operating Officer, Daniel Bensen, sold 131,411 shares of common stock in November 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Daniel Bensen, Chief Operating Officer of Tyra Biosciences, Inc. (TYRA), reported sales of common stock.
• A total of 131,411 shares were sold across four separate transactions between November 13, 2025, and November 17, 2025.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Bensen on November 5, 2024.
• The weighted average sale prices ranged from $16.0036 to $17.0713 per share.
• Following these transactions, Mr. Bensen beneficially owns 296,570 shares of Tyra Biosciences common stock.

Sentiment

Score: 5

Explanation: The filing reports pre-scheduled insider sales, which are neutral in isolation but can sometimes be perceived negatively by the market.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a structured and pre-scheduled transaction rather than a discretionary sale based on new, adverse information.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived by the market as a lack of confidence or a signal that the stock price may be nearing a peak.

Risks

• Potential negative market perception due to insider selling, which could lead to short-term stock price volatility.

Future Outlook

NA

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders might interpret the insider sales as a signal, potentially influencing their investment decisions, despite the pre-planned nature of the transactions.

Key Dates

Recommendation

The sales by the Chief Operating Officer were executed under a pre-arranged Rule 10b5-1 trading plan, which typically indicates a personal financial planning event rather than a reaction to new material non-public information. While insider selling can sometimes create negative sentiment, the structured nature of these transactions mitigates concerns about immediate adverse company developments. Investors should maintain their current position, monitoring future company performance and broader market trends rather than reacting solely to these pre-scheduled sales.

Keywords

Tyra Biosciences, TYRA, Insider Sale, Form 4, Daniel Bensen, 10b5-1 Plan, Common Stock